Bayer jumps on board Mammoth's ultra-small CRISPR tech with sights set first on the liver
German drug giant Bayer has looked to reinvent itself in recent years, moving on from its past as a primarily consumer health brand into one built around next-gen therapies. Now, Bayer is taking a flyer on one of the children of CRISPR maven Jennifer Doudna’s hallowed lab working on tiny versions of the gene editing tech.
Bayer will pay $40 million upfront and more than $1 billion in potential downstream milestones for up to five in vivo gene editing candidates from Mammoth Biosciences, a Doudna lab spinout developing ultra-small enzymes for easier packaging and delivery into cells, the partners said Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.